Ticker Details
Iovance Biotherapeutics, Inc. Iovance Biotherapeutics Inc is a biopharmaceutical company in the United States. Its lead pipeline candidate, LN-144, uses the tumor-infiltrating lymphocytes to treat serious diseases.
IPO Date:	October 23, 2013
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.52B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.44 | 3.22%
Avg Daily Range (30 D):	$0.15 | 3.85%
Avg Daily Range (90 D):	$0.14 | 4.29%

Institutional Daily Volume
Avg Daily Volume:	4.2M
Avg Daily Volume (30 D):	13.25M
Avg Daily Volume (90 D):	13.46M

Trade Size
Avg Trade Size (Sh.):	188
Avg Trade Size (Sh.) (30 D):	285
Avg Trade Size (Sh.) (90 D):	344

Institutional Trades
Total Institutional Trades:	5,523
Avg Institutional Trade:	$2.54M
Avg Institutional Trade (30 D):	$2.72M
Avg Institutional Trade (90 D):	$2.41M
Avg Institutional Trade Volume:	.24M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$3.88M
Avg Closing Trade (30 D):	$3.94M
Avg Closing Trade (90 D):	$3.11M
Avg Closing Volume:	398.24K

News

Apr 10, 2026 @ 4:30 PM Is This Biotech Stock the Best Chance to Make a Fo... Source: Prosper Junior Bakiny

Apr 1, 2026 @ 8:43 AM Proleukin Market Research Report 2026-2035: Epidem... Source: Researchandmarkets.Com

Apr 1, 2026 @ 12:49 AM The $578 Billion Regenerative Medicine Market Has ... Source: Usa News Group

Mar 5, 2026 @ 10:27 PM Iovance Biotherapeutics: The High‑Risk Canc... Source: Prosper Junior Bakiny

Feb 23, 2026 @ 8:15 AM 1 Nearly Unknown Biotech Stock Set To Go Parabolic... Source: Adria Cimino

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS		$-.25	$-.33
Diluted EPS			$-.33
Revenue		$67.46M	$59.95M
Gross Profit		$28.98M	$3.29M
Net Income / Loss		$-91.25M	$-111.66M
Operating Income / Loss		$-94.9M	$-113.77M
Cost of Revenue		$38.48M	$56.66M
Net Cash Flow		$25.69M	$-39.64M
PE Ratio

Splits
Sep 26, 2013	1:100
Apr 06, 2010	24:1